The Maine Legislature is currently in discussions regarding new testing requirements for medical cannabis, highlighting ongoing disagreements over existing regulations. Since the legalization of medical cannabis in 1999, Maine has not mandated comprehensive contaminant and potency testing, creating a stark contrast with the rigorous testing protocols established for the adult-use cannabis market, which was approved by voters in 2016.
Rep. Marc Malon (D-Biddeford) noted that this inconsistency “doesn’t pass the smell test,” referring to a proposal that aligns with Governor Janet Mills’ vision for medical program testing. In her recent State of the State address, Mills emphasized the need to regulate the medical cannabis market more strictly, stating, “We cannot continue to encourage the wild, wild west of medical cannabis.”
Disparities in Testing Authority
Some legislators and cannabis industry stakeholders argue that the state is not adequately utilizing its current testing authority. Central to the controversy is how the rules set by the Office of Cannabis Policy relate to state law. Notably, neither the existing rules for medical cannabis nor the statute explicitly detail the parameters and penalties for what constitutes a failed test—a framework that exists within the recreational sector.
Alexis Soucy, director of media relations for the Office of Cannabis Policy, explained, “The medical program statute does not specify the requirements necessary for the office to implement a mandatory contaminant testing program.” Critics contend that the administration’s proposed measures would effectively drive many operators out of business.
Recent Legislative History
The medical cannabis program rules were last updated in February 2018, enacting requirements for annual inspections of dispensaries and sample testing for pesticides. However, caregivers—individuals licensed to grow and sell medical cannabis—are not subjected to similar mandates. The 2018 legislative overhaul allowed registered caregivers to operate storefronts and employ an unlimited number of staff without incorporating the testing authority specified in earlier versions of the statute.
Disagreements persist regarding the enforceability of the rules set forth. Sen. Craig Hickman (D-Kennebec) and other legislators assert that these rules are indeed enforceable, countering Soucy’s claims that they lack statutory backing. Rep. David Boyer (R-Poland) echoed this, insisting that adequate regulations are in place and calling for immediate testing measures.
Challenges to Implementation
The Office of Cannabis Policy currently does not perform annual inspections or testing for every dispensary or caregiver under either the medical or adult-use cannabis programs, attributing this shortcoming to inadequate staffing. Soucy emphasized that without statutory clarifications regarding harmful contaminant levels, the office’s capacity to act based on test results remains limited.
In 2023, the office collected samples from registered caregivers for a study, suggesting a need for program reform due to alarming results revealing excess levels of harmful substances, including myclobutanil—a chemical that poses significant health risks.
The study highlighted serious safety concerns, with over 40% of samples testing positive for banned materials, including myclobutanil. However, many failures were also related to naturally occurring mold and yeast, raising questions about the scientific basis for current thresholds.
During discussions among lawmakers, agricultural scientist Rep. Laurie Osher (D-Orono) pointed out that existing regulations might hinder certain growers by penalizing naturally occurring microbes essential for healthy cultivation. Such regulatory discussions reflect the broader implications for the cannabis market in Maine as the state seeks to balance public health and safety with industry viability.
Assistant Majority Leader Jill Duson (D-Cumberland) concluded recent committee meetings by emphasizing the need for clear oversight authority for the Office of Cannabis Policy, underscoring the importance of regulatory clarity in the evolving landscape of medical cannabis in Maine.